Is baricitinib/baricitinib really used to treat rheumatoid arthritis?

Baricitinib(Baricitinib) is indeed an oral targeted drug that is widely used to treat rheumatoid arthritis (Rheumatoid Arthritis, RA). It is a Janus kinase (JAK) inhibitor that blocks the JAK1 and JAK2 signaling pathways and interferes with the signaling of multiple pro-inflammatory cytokines, thereby effectively inhibiting the inflammatory response of rheumatoid arthritis. Rheumatoid arthritis is a chronic autoimmune disease that mainly affects the synovium of joints, causing pain, swelling, limited movement, and even destruction of joint structures, seriously affecting the patient's quality of life. Although traditional treatments such as methotrexate can relieve symptoms, some patients have poor efficacy or poor tolerance. Therefore, new drugs that are more precise and more effective are needed.

Baricitinib was developed and approved against the backdrop of this demand. According to multiple studies and guidelines in Europe and the United States, it is mainly suitable for patients with moderately to severely active rheumatoid arthritis, especially those who have poor response to one or more traditional anti-rheumatic drugs (csDMARDs). Baricitinib significantly reduces joint pain, improves joint function and slows structural damage when used in combination with methotrexate or alone. A major advantage of this drug is the oral administration method, which avoids the discomfort of injection of biologic drugs and facilitates long-term use.

Baricitinib has also been included in many treatment recommendation guidelines including the American College of Rheumatology (ACR) and the European League Against Rheumatism (EULAR), and is listed as one of the first-line or alternative treatment options. Its safety has also been proven in clinical practice, and although there may be risks of infection (such as herpes zoster) or thrombophilia, it can be managed well under physician monitoring.

Reference materials:https://go.drugbank.com/drugs/DB11817